ketanserin has been researched along with Cardiovascular Diseases in 15 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ketanserin is an agent whose main pharmacologic action is antagonism of serotonin (5-hydroxytryptamine, 5HT) receptors of the 5HT2 subtype." | 6.37 | Effects of a new serotonin antagonist, ketanserin, in experimental and clinical hypertension. ( Hedner, T; Persson, B, 1988) |
| "To determine whether ketanserin, an antagonist at the serotonin receptor, prevents important vascular events such as death, myocardial infarction, major stroke, and amputation of a leg in patients with claudication." | 5.06 | Prevention of atherosclerotic complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group. ( , 1989) |
| " Ketanserin is a highly selective S2-serotonergic antagonist with additional alpha-adrenergic blocking activity, which has been proposed as a therapy for various cardiovascular diseases including hypertension." | 4.79 | Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. ( Frishman, WH; Huberfeld, S; Kumar, A; Okin, S; Shareef, B; Wang, YH, 1995) |
| "Ketanserin is an agent whose main pharmacologic action is antagonism of serotonin (5-hydroxytryptamine, 5HT) receptors of the 5HT2 subtype." | 2.37 | Effects of a new serotonin antagonist, ketanserin, in experimental and clinical hypertension. ( Hedner, T; Persson, B, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (60.00) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elbers, PW | 1 |
| Ozdemir, A | 1 |
| van Iterson, M | 1 |
| van Dongen, EP | 1 |
| Ince, C | 1 |
| Frishman, WH | 2 |
| Huberfeld, S | 1 |
| Okin, S | 1 |
| Wang, YH | 1 |
| Kumar, A | 1 |
| Shareef, B | 1 |
| Grewall, P | 1 |
| Lüscher, TF | 1 |
| Tanner, FC | 1 |
| Bühler, FR | 1 |
| van Zwieten, PA | 1 |
| Blauw, GJ | 1 |
| van Brummelen, P | 1 |
| Prichard, BN | 1 |
| Smith, CC | 1 |
| De Cree, J | 3 |
| Leempoels, J | 2 |
| Demoen, B | 2 |
| Roels, V | 3 |
| Verhaegen, H | 3 |
| Frohlich, ED | 1 |
| Leysen, JE | 1 |
| Wynants, J | 1 |
| Eens, A | 1 |
| Janssen, PA | 1 |
| Zanchetti, A | 1 |
| Hedner, T | 1 |
| Persson, B | 1 |
5 reviews available for ketanserin and Cardiovascular Diseases
| Article | Year |
|---|---|
Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Coronary Disease; | 1995 |
Serotonin and the heart.
Topics: Animals; Antihypertensive Agents; Arteriosclerosis; Blood Pressure; Cardiovascular Diseases; Endothe | 2000 |
[Serotonin and cardiovascular diseases. Pathophysiology and significance of serotonin antagonists].
Topics: Aged; Animals; Arterial Occlusive Diseases; Blood Platelets; Cardiovascular Diseases; Cerebrovascula | 1992 |
Pathophysiological and pharmacotherapeutic aspects of serotonin and serotonergic drugs.
Topics: Animals; Antihypertensive Agents; Cardiovascular Diseases; Humans; Hypertension; Ketanserin; Piperaz | 1990 |
Effects of a new serotonin antagonist, ketanserin, in experimental and clinical hypertension.
Topics: Animals; Antihypertensive Agents; Cardiovascular Diseases; Cardiovascular System; Dose-Response Rela | 1988 |
3 trials available for ketanserin and Cardiovascular Diseases
| Article | Year |
|---|---|
Effect of ketanserin on the hyperreactivity of platelets to 5-hydroxytryptamine in patients with cardiovascular diseases.
Topics: Adult; Aged; beta-Thromboglobulin; Blood Platelets; Cardiovascular Diseases; Double-Blind Method; Hu | 1985 |
Prevention of atherosclerotic complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group.
Topics: Adult; Amputation, Surgical; Arteriosclerosis; Cardiovascular Diseases; Cause of Death; Cerebrovascu | 1989 |
The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseases.
Topics: Aged; Arterial Occlusive Diseases; beta-Thromboglobulin; Cardiovascular Diseases; Double-Blind Metho | 1985 |
7 other studies available for ketanserin and Cardiovascular Diseases
| Article | Year |
|---|---|
Microcirculatory imaging in cardiac anesthesia: ketanserin reduces blood pressure but not perfused capillary density.
Topics: Adult; Aged; Anesthesia; Blood Pressure; Capillaries; Cardiac Surgical Procedures; Cardiovascular Di | 2009 |
Serotonin: receptors and antagonists--summary of symposium.
Topics: Animals; Cardiovascular Diseases; Humans; Ketanserin; Receptors, Serotonin; Serotonin; Serotonin Ant | 1990 |
The role of serotonin in cardiovascular disease.
Topics: Cardiovascular Diseases; Humans; Hypertension; Ketanserin; Serotonin | 1987 |
Ketanserin reduces a particular monoamine pool in peripheral tissues.
Topics: Age Factors; Animals; Brain Chemistry; Cardiovascular Diseases; Catecholamines; Humans; Ketanserin; | 1989 |
Serotonin and cardiovascular regulation: a new approach to hypertension.
Topics: Cardiovascular Diseases; Drug Therapy, Combination; Humans; Hypertension; Ketanserin; Piperidines; S | 1986 |
The role of serotonin in cardiovascular disease. Proceedings of a symposium. Kyoto, 27 May 1988.
Topics: Animals; Cardiovascular Diseases; Humans; Ketanserin; Serotonin | 1988 |
Hyperreactivity of platelets to serotonin (5-hydroxytryptamine) in patients with cardiovascular diseases. Influence of ketanserin, a serotonin S2-receptor antagonist.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Humans; Ketanserin; Middle Aged; Platelet A | 1988 |